Airway inflammation enhances the effectiveness of elexacaftor-tezacaftor-ivacaftor therapy for cystic fibrosis and CFTR^N1303K mutation

Affiliations

• ¹ Marsico Lung Institute and Cystic Fibrosis Research Center, The University of North Carolina, Chapel Hill, NC 27599, USA; Department of Pediatrics, The University of North Carolina, Chapel Hill, NC 27599, USA; Department of Cell Biology and Physiology, The University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: gentzsch@med.unc.edu.
• ² Marsico Lung Institute and Cystic Fibrosis Research Center, The University of North Carolina, Chapel Hill, NC 27599, USA; Department of Pediatrics, The University of North Carolina, Chapel Hill, NC 27599, USA.
• ³ Marsico Lung Institute and Cystic Fibrosis Research Center, The University of North Carolina, Chapel Hill, NC 27599, USA; Department of Cell Biology and Physiology, The University of North Carolina, Chapel Hill, NC 27599, USA; Department of Medicine, The University of North Carolina, Chapel Hill, NC 27599, USA.